209 related articles for article (PubMed ID: 32336542)
1. Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis.
Wang K; Song Y; Su Y; Liang Y; Wang L
Biochem Biophys Res Commun; 2020 Jun; 527(2):453-457. PubMed ID: 32336542
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
3. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
4. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
[TBL] [Abstract][Full Text] [Related]
5. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
[TBL] [Abstract][Full Text] [Related]
6. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
[TBL] [Abstract][Full Text] [Related]
7. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
[TBL] [Abstract][Full Text] [Related]
8. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
Molecules; 2019 May; 24(11):. PubMed ID: 31151293
[TBL] [Abstract][Full Text] [Related]
9. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
[TBL] [Abstract][Full Text] [Related]
10. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis.
Zyla E; Musielak B; Holak TA; Dubin G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443436
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy.
Bojko M; Węgrzyn K; Sikorska E; Kocikowski M; Parys M; Battin C; Steinberger P; Kogut MM; Winnicki M; Sieradzan AK; Spodzieja M; Rodziewicz-Motowidło S
Bioorg Chem; 2022 Nov; 128():106047. PubMed ID: 35963023
[TBL] [Abstract][Full Text] [Related]
12. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
[TBL] [Abstract][Full Text] [Related]
13. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold.
Qin M; Cao Q; Wu X; Liu C; Zheng S; Xie H; Tian Y; Xie J; Zhao Y; Hou Y; Zhang X; Xu B; Zhang H; Wang X
Eur J Med Chem; 2020 Jan; 186():111856. PubMed ID: 31734021
[TBL] [Abstract][Full Text] [Related]
15. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Lin X; Lu X; Luo G; Xiang H
Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
17. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor.
Li Q; Quan L; Lyu J; He Z; Wang X; Meng J; Zhao Z; Zhu L; Liu X; Li H
Oncotarget; 2016 Oct; 7(40):64967-64976. PubMed ID: 27533458
[TBL] [Abstract][Full Text] [Related]
18. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.
Wang T; Wu X; Guo C; Zhang K; Xu J; Li Z; Jiang S
J Med Chem; 2019 Feb; 62(4):1715-1730. PubMed ID: 30247903
[TBL] [Abstract][Full Text] [Related]
19. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
